Reducing Episodic Cluster Headaches: Focus on Galcanezumab

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Reducing Episodic Cluster Headaches : Focus on Galcanezumab. / Pellesi, Lanfranco; De Icco, Roberto; Al-Karagholi, Mohammad Al-Mahdi; Ashina, Messoud.

I: Journal of Pain Research, Bind 13, 2020, s. 1591-1599.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Pellesi, L, De Icco, R, Al-Karagholi, MA-M & Ashina, M 2020, 'Reducing Episodic Cluster Headaches: Focus on Galcanezumab', Journal of Pain Research, bind 13, s. 1591-1599. https://doi.org/10.2147/JPR.S222604

APA

Pellesi, L., De Icco, R., Al-Karagholi, M. A-M., & Ashina, M. (2020). Reducing Episodic Cluster Headaches: Focus on Galcanezumab. Journal of Pain Research, 13, 1591-1599. https://doi.org/10.2147/JPR.S222604

Vancouver

Pellesi L, De Icco R, Al-Karagholi MA-M, Ashina M. Reducing Episodic Cluster Headaches: Focus on Galcanezumab. Journal of Pain Research. 2020;13:1591-1599. https://doi.org/10.2147/JPR.S222604

Author

Pellesi, Lanfranco ; De Icco, Roberto ; Al-Karagholi, Mohammad Al-Mahdi ; Ashina, Messoud. / Reducing Episodic Cluster Headaches : Focus on Galcanezumab. I: Journal of Pain Research. 2020 ; Bind 13. s. 1591-1599.

Bibtex

@article{ec816562ac334bffbee6c5ad07f3ca57,
title = "Reducing Episodic Cluster Headaches: Focus on Galcanezumab",
abstract = "The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for the prevention of cluster headache. Two clinical trials have been conducted to investigate the efficacy and safety of galcanezumab in episodic cluster headache and chronic cluster headache. While efficacy endpoints were not met in the chronic subtype, galcanezumab reduced the weekly frequency of attacks in patients with episodic cluster headaches. In both studies, the antibody was well tolerated. This review summarizes and critically reviews the available data regarding the rationale behind targeting the calcitonin gene-related peptide with galcanezumab for the prevention of cluster headache.",
author = "Lanfranco Pellesi and {De Icco}, Roberto and Al-Karagholi, {Mohammad Al-Mahdi} and Messoud Ashina",
note = "{\textcopyright} 2020 Pellesi et al.",
year = "2020",
doi = "10.2147/JPR.S222604",
language = "English",
volume = "13",
pages = "1591--1599",
journal = "Journal of Pain Research",
issn = "1178-7090",
publisher = "Dove Medical Press",

}

RIS

TY - JOUR

T1 - Reducing Episodic Cluster Headaches

T2 - Focus on Galcanezumab

AU - Pellesi, Lanfranco

AU - De Icco, Roberto

AU - Al-Karagholi, Mohammad Al-Mahdi

AU - Ashina, Messoud

N1 - © 2020 Pellesi et al.

PY - 2020

Y1 - 2020

N2 - The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for the prevention of cluster headache. Two clinical trials have been conducted to investigate the efficacy and safety of galcanezumab in episodic cluster headache and chronic cluster headache. While efficacy endpoints were not met in the chronic subtype, galcanezumab reduced the weekly frequency of attacks in patients with episodic cluster headaches. In both studies, the antibody was well tolerated. This review summarizes and critically reviews the available data regarding the rationale behind targeting the calcitonin gene-related peptide with galcanezumab for the prevention of cluster headache.

AB - The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for the prevention of cluster headache. Two clinical trials have been conducted to investigate the efficacy and safety of galcanezumab in episodic cluster headache and chronic cluster headache. While efficacy endpoints were not met in the chronic subtype, galcanezumab reduced the weekly frequency of attacks in patients with episodic cluster headaches. In both studies, the antibody was well tolerated. This review summarizes and critically reviews the available data regarding the rationale behind targeting the calcitonin gene-related peptide with galcanezumab for the prevention of cluster headache.

U2 - 10.2147/JPR.S222604

DO - 10.2147/JPR.S222604

M3 - Review

C2 - 32753938

VL - 13

SP - 1591

EP - 1599

JO - Journal of Pain Research

JF - Journal of Pain Research

SN - 1178-7090

ER -

ID: 250432459